Sign In
Buy VIVO
$3.90
+0.170 (+4.56%)
At Close: Aug 04, 2026
Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay
09:25am, Monday, 28'th Jun 2021
CINCINNATI, June 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submit
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
06:48pm, Thursday, 24'th Jun 2021
Meridian Bioscience (VIVO) closed the most recent trading day at $20.90, moving +0.87% from the previous trading session.
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
06:48pm, Monday, 14'th Jun 2021
In the latest trading session, Meridian Bioscience (VIVO) closed at $20.88, marking a +1.11% move from the previous day.
Meridian Bioscience to Participate in the 41st Annual William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference
10:00am, Thursday, 27'th May 2021
CINCINNATI, May 27, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today participation in two upcoming investor conferences. Jack Kenny, Chief Executive Officer, will part
IYH: Healthcare Dashboard For May
03:31pm, Monday, 17'th May 2021
IYH: Healthcare Dashboard For May
Meridian Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples
10:00am, Monday, 17'th May 2021
CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
06:47pm, Friday, 07'th May 2021
Meridian Bioscience (VIVO) closed at $20.45 in the latest trading session, marking a +6.68% move from the prior day.
Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q2 2021 Results - Earnings Call Transcript
01:32pm, Friday, 07'th May 2021
Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q2 2021 Results - Earnings Call Transcript
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021
07:30am, Friday, 07'th May 2021
CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.
Meridian Simplifies Workflows for POC Molecular Tests with a New Lyo-Ready™ LAMP Mix
02:00pm, Wednesday, 28'th Apr 2021
CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Ly
A Trio of High-Return, Non-Cyclical Stocks for the Value Investor
02:38pm, Thursday, 22'nd Apr 2021
If you are screening the market for high-return investments, you may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, P
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
06:48pm, Wednesday, 21'st Apr 2021
Meridian Bioscience (VIVO) closed at $22.43 in the latest trading session, marking a +1.72% move from the prior day.
Meridian Bioscience to Hold Second Quarter Fiscal 2021 Financial Results Conference Call on May 7, 2021
02:00pm, Monday, 19'th Apr 2021
CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 20
Meridian Bioscience (VIVO) Dips More Than Broader Markets: What You Should Know
06:59pm, Wednesday, 14'th Apr 2021
Meridian Bioscience (VIVO) closed the most recent trading day at $23.94, moving -1.4% from the previous trading session.
GenomeWeb Index Drops 3% for 2nd Consecutive Month
05:10pm, Tuesday, 13'th Apr 2021
Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% i
